Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments (2019 - 2025)

BridgeBio Pharma's Cash & Current Investments history spans 7 years, with the latest figure at $17.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 95.17% year-over-year to $17.4 million; the TTM value through Sep 2025 reached $645.9 million, up 59.2%, while the annual FY2025 figure was $17.4 million, 95.17% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $17.4 million at BridgeBio Pharma, down from $645.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $919.1 million in Q1 2021 and bottomed at $17.4 million in Q4 2025.
  • The 5-year median for Cash & Current Investments is $475.4 million (2024), against an average of $514.6 million.
  • The largest YoY upside for Cash & Current Investments was 85.53% in 2025 against a maximum downside of 95.17% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $393.9 million in 2021, then grew by 5.25% to $414.6 million in 2022, then rose by 4.89% to $434.9 million in 2023, then decreased by 17.27% to $359.8 million in 2024, then plummeted by 95.17% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cash & Current Investments are $17.4 million (Q4 2025), $645.9 million (Q3 2025), and $756.9 million (Q2 2025).